A post-hoc analysis of the Phase IIIb SURMOUNT-MAINTAIN trial examined the correlation between cardiometabolic parameters and weight reduction maintenance in tirzepatide treatment when the dose was reduced from the maximum tolerated dose (MTD) to 5 mg. Image credit: [agustin.photo]/Shutterstock.com

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.

With a free Pharmaceutical Technology profile, you can:

  • Access exclusive analyst commentary and expert insights
  • View premium forecasts and data-driven pharmaceutical industry insights
  • Stay up to date with pharma news, manufacturing innovation, and regulatory developments
  • Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here

Powered by